- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.07. | Biogen defends anti-tau drug after stock slides on Alzheimer's readout | ||
| 14.07. | Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer | ||
| 14.07. | Summit sells failed antibiotic to OpenAI-backed startup in $105M deal | ||
| 14.07. | Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal | ||
| 13.07. | Merck KGaA institutes in-office requirement for US research team that could lead to 70 layoffs | ||
| 13.07. | FDA releases 14 new drug rejection letters after 3-month pause in transparency policy | ||
| 13.07. | Q32's stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors | ||
| 13.07. | Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancer | ||
| 13.07. | Insilico's Chinese partner returns for $177M pact to explore 'mass market' CNS indication | ||
| 10.07. | GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its 'priority asset' | ||
| 10.07. | Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail | ||
| 09.07. | Roche ends 2 Huntington's disease programs, including Ionis-partnered tominersen | ||
| 09.07. | Fate's off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease | ||
| 09.07. | GSK cuts losses on $700M upfront Alzheimer's collab with Alector following 2 clinical failures | ||
| 08.07. | Prime wins patent fight with Beam to continue work on AATD gene editing therapy | ||
| 08.07. | Satellos' 'intriguing' Duchenne data raise hopes ahead of key readout | ||
| 08.07. | Scipher picks up Chemomab's rheumatoid arthritis drug, Nasdaq listing in all-stock merger | ||
| 08.07. | AstraZeneca pens $2.1B Sino deal for challenger to Merck's COPD drug Ohtuvayre | ||
| 07.07. | MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization | ||
| 07.07. | Whitehawk swoops in for five ADCs via development deal with China's Biocytogen | ||
| 07.07. | Boehringer bags PVT's viral vector platform for cancer vaccine R&D | ||
| 07.07. | As US lawmakers increase scrutiny of Chinese trials, industry fears 'huge distraction and expense' | ||
| 07.07. | Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s | ||
| 07.07. | Kailera's oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials | ||
| 06.07. | Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.